Stayble Therapeutics
0.234 SEK -6.41%Be the first to follow this company
Stayble Therapeutics operates in the pharmaceutical industry. The company specializes in the research and development of injection treatments for chronic degenerative back pain. The drug candidates are developed and based on a self-developed technological platform. Stayble Therapeutics operates on the Nordic market and is headquartered in Gothenburg.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
STABL
Daily low / high price
0.231 / 0.25
SEK
Market cap
7.41M SEK
Turnover
33.23K SEK
Volume
138K
Financial calendar
General meeting
2024-05-15
Interim report
2024-05-21
Interim report
2024-08-20
Interim report
2024-11-19
Annual report
2025-02-25
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Stiftelsen Chalmers Tekniska Högskola | 10.6 % | 10.6 % |
Avanza Pension | 6.5 % | 6.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Kallelse till årsstämma i Stayble Therapeutics AB
Stayble Therapeutics: Abstract om STA363s kliniska effekt på diskvolym har accepterats för presentation vid viktig kongress
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools